Awardee OrganizationUNIVERSITY OF MARYLAND BALTIMORE
Description
Abstract Text
Prolactin (PRL), an anterior pituitary hormone, has profound effects on
female fertility. In fact, hypersecretion of PRL is the major
neuroendocrine-related pathology associated with female infertility.
Unfortunately, the underlying defects which lead to the hypersecretion of
PRL remain ill-defined. To provide a rational framework for understanding
these defects and treating associated pathologies, it is essential to
elucidate the cellular and molecular mechanisms of PRL secretion
regulation. Normally, PRL secretion is under tonic inhibition by
hypothalamic dopamine (DA). Periodic, physiological surges of PRL in
females require a withdrawal from this dopaminergic inhibition. Since
reduced responsiveness to DA is a hallmark of hyperprolactinemic
syndromes, our attention has focused on the cellular and molecular basis
of DA action on the lactotrope.
We have discovered and extensively characterized a DA-activated inwardly-
rectifying potassium channel (K/DA) in normal lactotropes. K/DA activation
by DA leads to hyperpolarization of the lactotrope membrane and cessation
of calcium-dependent action potentials, the driving force for tonic PRL
secretion. In vitro studies have demonstrated a critical role for this
D/DA channel in the regulation of PRL release by DA. Furthermore, the
functional expression of D/DA is dependent upon estrogen, which may
explain a long-recognized modulatory action of estrogen on this system. In
these regards, the D/DA channel lies at the top of a hierarchy of events
in dopaminergic regulation of PRL secretion.
As an initial step in elucidating the molecular basis for the
physiological role of K/DA in lactotropes, we have cloned three different
K channel gene products from female anterior pituitary tissue. Based on
functional similarities between the native channel and recombinant
channels expressed in Xenopus oocytes, two of the gene products are
excellent candidate subunits encoding a heteromultimeric K/DA. As a
logical extension of these studies, we propose to evaluate the role of
this effector K channel within its physiological context-the whole animal-
through transgenic technology. To this end, we will design and construct
"dominant-negative" mutants, capable of inhibiting wild-type K/DA function
in lactotropes. We will then create a transgenic mouse model in which
expression of this mutant is directed to pituitary lactotropes using the
PRL promoter. These studies represent a timely and important extension of
the P.I.'s work and will ultimately provide insight into the basis of
disorders in PRL secretion and their impact on female fertility.
Eunice Kennedy Shriver National Institute of Child Health and Human Development
CFDA Code
DUNS Number
188435911
UEI
Z9CRZKD42ZT1
Project Start Date
01-April-1999
Project End Date
31-March-2000
Budget Start Date
01-October-1998
Budget End Date
30-September-1999
Project Funding Information for 1999
Total Funding
$139,589
Direct Costs
Indirect Costs
Year
Funding IC
FY Total Cost by IC
1999
Eunice Kennedy Shriver National Institute of Child Health and Human Development
$139,589
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U54HD036207-02 0001
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U54HD036207-02 0001
Patents
No Patents information available for 5U54HD036207-02 0001
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U54HD036207-02 0001
Clinical Studies
No Clinical Studies information available for 5U54HD036207-02 0001
News and More
Related News Releases
No news release information available for 5U54HD036207-02 0001
History
No Historical information available for 5U54HD036207-02 0001
Similar Projects
No Similar Projects information available for 5U54HD036207-02 0001